Clinical Test for HPV Induced Cancer in Low Resource Settings Via Direct Detection of Elevated HPV E6 Oncoprotein

Schweizer, J1, Belmares, M1, Charles, S1, Gaillard, E1, Petrauskene, O1, Reveilhe, S1, Tajan, E1, Tan, C1, Castle, PE2, Jeronimo, J3, Qiao, YL4, Effah, K5, Kaufmann, AM6, Lu, P1

1 Arbor Vita Corp., Fremont, CA, USA; 2 Global Coalition Against Cervical Cancer, Arlington, VA, USA; 3 PATH, Seattle, WA, USA; 4 Cancer Institute and Hospital, Beijing, China; 5 Catholic Hospital Battor, Ghana; 6 Charité Hospital, Berlin, Germany

Download PDF

FOR PROFESSIONALS

Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer

Clinical Test for HPV Induced Cancer in Low Resource Settings Via Direct Detection of Elevated HPV E6 Oncoprotein

Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china

Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species

The Human Papillomavirus E6 Oncogene Dysregulates the Cell Cycle and Contributes to Cervical Carcinogenesis through Two Independent Activities